COVID-19 vaccine induced interstitial lung disease
| Autor: | Haruhiko Hoshino, Shuntaro Suda, Yoshifumi Uwamino, Hiromi Miyahara, Saori Murata, Ayumi Yoshifuji, Motoko Fujino, Naoki Hasegawa, Kazuhiko Sekine, Yuya Masuzawa, Munekazu Ryuzaki, Kota Ishioka |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Male 2019-20 coronavirus outbreak COVID-19 Vaccines Coronavirus disease 2019 (COVID-19) Case Report Disease medicine.disease_cause medicine Humans Pharmacology (medical) Adverse effect Lung Coronavirus medicine.diagnostic_test business.industry SARS-CoV-2 Interstitial lung disease COVID-19 drug-induced interstitial lung disease Middle Aged medicine.disease adverse events Infectious Diseases Bronchoalveolar lavage Dyspnea Immunology business Lung Diseases Interstitial COVID-19 vaccine CD8 |
| Zdroj: | Journal of Infection and Chemotherapy |
| ISSN: | 1437-7780 |
| Popis: | A 60-year-old man presented with dyspnea four days after the second dose of the coronavirus disease (COVID-19) vaccine. Imaging revealed extensive ground-glass opacification. Blood tests were notable for elevated KL-6 levels. Bronchoalveolar lavage fluid analysis showed increased lymphocyte-dominant inflammatory cells and decreased CD4/CD8 ratio. These findings were consistent with the diagnosis of drug-induced interstitial lung disease (DIILD). To the best of our knowledge, this has never been reported in previous literature. Treatment with glucocorticoids relieved his symptoms. This paper highlights that although extremely rare, COVID-19 vaccine could cause DIILD, and early diagnosis and treatment are crucial to improve patient outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect